Altimmune Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Altimmune, Inc. (ALT) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Operating Activities
Net Income-95.06-88.45-84.71-97.09-49.04-20.52
Depreciation & Amortization0.240.48-0.200.550.430.39
Deferred Income Tax0.000.000.000.000.00-0.06
Stock Based Compensation14.3910.648.105.522.580.00
Change in Working Capital4.48-8.2711.07-0.252.621.76
Change in Accounts Receivable0.57-0.940.264.18-3.590.00
Change in Accounts Payable-1.86-2.732.771.420.590.00
Change in Other Working Capital4.60-3.230.09-8.215.620.00
Other Operating Activities-0.05-0.1511.141.08-4.568.78
Net Cash from Operating Activities-79.85-75.81-62.59-78.24-50.57-9.60
Investing Activities
Capital Expenditures0.00-0.050.13-12.120.340.03
Acquisitions0.000.000.090.7016.270.00
Purchases of Investments-28.3913.78-73.2799.84-71.880.00
Sales/Maturities of Investments87.35102.41-73.27-0.20-71.88-28.26
Other Investing Activities0.000.000.000.7016.270.00
Net Cash from Investing Activities-28.3913.73-73.4087.52-55.96-28.29
Financing Activities
Debt Repayment0.000.000.000.00-0.63-0.29
Common Stock Issued10.8986.9356.3565.2248.2912.67
Common Stock Repurchased-0.85-0.54-0.520.000.000.00
Other Financing Activities-0.85-0.29-0.52-0.120.000.15
Net Cash from Financing Activities10.0486.1156.7865.10213.4912.53
Summary
Net Change in Cash-98.1924.03-79.2074.38106.96-25.36
Cash at Beginning of Period135.16111.13190.34115.959.0034.35
Cash at End of Period36.97135.16111.13190.34115.959.00
Free Cash Flow-79.85-75.86-62.71-90.36-50.91-9.63
Supplemental Disclosures
Interest Paid0.000.000.000.000.000.00